You are here:

Jindřich Henry Kopeček

Distinguished Professor of Pharmaceutics & Pharmaceutical Chemistry
and Distinguished Professor of Bioengineering

Kopecek Photo

M.S. Institute of Chemical Technology, Czechoslovakia

Ph.D. Institute of Macromolecular Chemistry, Czechoslovakia

D.Sc. Czechoslovak Academy of Sciences, Czechoslovakia

Research

References

Jindřich.Kopecek@utah.edu

Jindřich Kopeček's Lab Page

Jindřich Kopeček's PubMed Literature Search

Biological Chemistry Program

Biorecognition & Drug Delivery

Research

Research in the Kopeček Biomedical Polymers Laboratory focuses on three areas: a) Macromolecular therapeutics with emphasis on development of polymeric drug carriers and novel therapeutic strategies; b) Design of smart biomaterials that self-assemble from hybrid copolymers composed of synthetic polymers and protein/peptide domains; c) Application of biomaterials biorecognition principles to biological systems – drug-free macromolecular therapeutics.

Macromolecular therapeutics
Recent research focuses on the design of backbone degradable, long-circulating polymer carrier – drug conjugates for the treatment of ovarian and prostate cancer and treatment of musculoskeletal diseases, especially osteoporosis. These second-generation conjugates have (when compared to the first generation) longer intravascular half-life and higher accumulation in tumor tissue. Combination therapy targeting both tumor-initiating and differentiated prostate cancer cell populations is also studied.

Smart biomaterials
The research centers on the design of polymer – peptide/protein hybrid biomaterials, whose self-assembly is mediated by coiled-coil and beta-sheet forming peptide domains. These materials are being evaluated as biomineralization matrices for bone tissue engineering and as 3D cell culture scaffolds.

Drug-free macromolecular therapeutics
A new therapeutic approach for the treatment of non-Hodgkin’s lymphoma has been developed.Formation of antiparallel coiled-coil heterodimers or hybridization of complementary oligonucleotides on B-cell surfaces results in crosslinking of CD20 receptors and apoptosis of Raji B cells. This is a new concept, where the biological activity of drug-free macromolecular therapeutics is based on the biorecognition of complementary motifs.

References

  1. Li L, Yang J, Wang J, Kopeček J (2017) Drug-Free Macromolecular Therapeutics Induce Apoptosis via Calcium Influx and Mitochondrial Signaling Pathway. Macromol. Biosci. doi: 10.1002/mabi.201700196
  2. Yang J, Kopeček J (2017) The Light at the End of the Tunnel – Second Generation HPMA Conjugates for Cancer Treatment. Curr. Opin. Colloid Interface Sci. http://dx.doi.org/10/.1016/j.cocis.2017.07.003
  3. Zhang L, Fang Y, Kopeček J, Yang J (2017) A New Construct of Antibody-Drug Conjugates for Treatment of Non-Hodgkin’s Lymphoma. Eur. J. Pharm. Sci. 103:36-46
  4. Yang J, Zhang R, Pan H, Li Y, Fang Y, Zhang L, Kopeček J (2017) Backbone Degradable HPMA Copolymer Conjugates with Gemcitabine and Paclitaxel: Impact of Molecular Weight on Activity toward Human Ovarian Carcinoma Xenografts. Mol. Pharmaceutics 14:1384-1394
  5. Zhang L, Fang Y, Yang J, Kopeček J (2017) Drug-Free Macromolecular Therapeutics: Impact of Structure on Induction of Apoptosis in Raji B Cells. J. Controlled Release doi: 10.1016/j.jconrel.2016.12.025
  6. Zhang R, Yang J, Radford DC, Fang Y, Kopeček J (2017) FRET Imaging of Enzyme-Responsive HPMA Copolymer Conjugate. Macromol. Biosci. 17:1600125; doi: 10.1002/mabi.201600125
  7. Low SA, Galliford CV, Jones-Hall YL, Roy J, Yang J, Low PS, Kopeček J (2017) Healing Efficacy of Fracture-Targeted GSK3b Inhibitor-Loaded Micelles for Improved Fracture Repair. Nanomedicine (Lond.) 12:185-193
  8. Hartley JM, Zhang R, Gudheti M, Yang J, Kopeček J (2016) Tracking and Quantifying Polymer Therapeutic Distribution on a Cellular Level Using 3D dSTORM. J. Controlled Release 231:50-59
  9. Zhang L, Zhang R, Yang J, Wang J, Kopeček J (2016) Indium-based and Iodine-based Labeling of HPMA Copolymer-Epirubicin Conjugates: Impact of Structure on the In Vivo Fate. J. Controlled Release 235:306-318
  10. Zhang R, Yang J, Zhou Y, Shami PJ, Kopeček J (2016) N-(2-Hydroxypropyl)methacrylamide Copolymer-drug Conjugates for Combination Chemotherapy of Acute Myeloid Leukemia. Macromol. Biosci. 16:121-128
  11. Yang J, Zhang R, Radford DC, Kopeček J (2015) FRET-Trackable Biodegradable HPMA Copolymer-Epirubicin Conjugates for Ovarian Carcinoma Therapy. J. Controlled Release 218:36-44
  12. Chu TW, Kopeček J (2015) Drug-Free Macromolecular Therapeutics – A New Paradigm in Polymeric Nanomedicines. Biomaterials Sci. 3:908-922
  13. Chu TW, Feng J, Yang J, Kopeček J (2015) Hybrid Polymeric Hydrogels via Peptide Nucleic Acid (PNA)/DNA Complexation. J. Controlled Release 220:608-616
  14. Chu TW, Zhang R, Yang J, Chao MP, Shami PJ, Kopeček J (2015) A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to Rituximab. Theranostics 5:834-846
  15. Peng ZH, Kopeček J (2015) Enhancing Accumulation and Penetration of HPMA Copolymer Doxorubicin Conjugates in 2D and 3D Prostate Cancer Cells via iRGD Conjugation with an MMP-2 Cleavable Spacer. J. Am. Chem. Soc. 137:6726-6729
  16. Zhang R, Yang J, Sima M, Zhou Y, Kopeček J (2014) Sequential Combination Therapy of Ovarian Cancer with Degradable N-(2-Hydroxypropyl)methacrylamide Copolymer Paclitaxel and Gemcitabine Conjugates. Proc. Natl. Acad. Sci. USA 111:12181-12186
  17. Zhou Y, Yang J, Rhim J, Kopeček J (2013) HPMA Copolymer-based Combination Therapy Toxic to both Prostate Cancer Stem/Progenitor Cells and Differentiated Cells Induces Durable Anti-tumor Effects. J. Controlled Release 172:946-953

to page top

Last Updated: 8/3/17